We are live on ! Find out more
EBS icon

Emergent Biosolutions

238 hedge funds and large institutions have $1.88B invested in Emergent Biosolutions in 2017 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 104 increasing their positions, 60 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

373% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 11

73% more repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 60

25% more capital invested

Capital invested by funds: $1.5B → $1.88B (+$378M)

20% more funds holding

Funds holding: 198238 (+40)

7.58% more ownership

Funds ownership: 90%97.58% (+7.6%)

47% less call options, than puts

Call options by funds: $684K | Put options by funds: $1.29M

Holders
238
Holders Change
+40
Holders Change %
+20.2%
% of All Funds
5.4%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
52
Increased
104
Reduced
60
Closed
11
Calls
$684K
Puts
$1.29M
Net Calls
-$609K
Net Calls Change
-$1.63M
Name Holding Trade Value Shares
Change
Change in
Stake
ASRS
76
Arizona State Retirement System
Arizona
$2.75M +$1.72M +40,978 +226%
Swiss National Bank
77
Swiss National Bank
Switzerland
$2.73M +$75.8K +1,800 +3%
AA
78
ALPS Advisors
Colorado
$2.7M +$222K +5,283 +10%
Nordea Investment Management
79
Nordea Investment Management
Sweden
$2.68M -$97.4K -2,315 -4%
New York State Common Retirement Fund
80
New York State Common Retirement Fund
New York
$2.67M -$154K -3,656 -6%
FP
81
Foundry Partners
Minnesota
$2.65M -$1.87M -44,496 -44%
HCM
82
Hodges Capital Management
Texas
$2.56M -$1.05M -25,000 -31%
California Public Employees Retirement System
83
California Public Employees Retirement System
California
$2.54M +$102K +2,419 +5%
California State Teachers Retirement System (CalSTRS)
84
California State Teachers Retirement System (CalSTRS)
California
$2.45M -$51.4K -1,222 -2%
3C
85
361 Capital
Colorado
$2.45M +$2.01M +47,637 +948%
VRS
86
Virginia Retirement Systems
Virginia
$2.43M -$181K -4,300 -8%
VOYA Investment Management
87
VOYA Investment Management
Georgia
$2.35M +$759K +18,020 +55%
Citigroup
88
Citigroup
New York
$2.2M -$274K -6,502 -12%
N
89
Nuveen
North Carolina
$2.19M -$352K -8,365 -15%
Canada Life
90
Canada Life
Manitoba, Canada
$2.15M -$50K -1,188 -3%
HIM
91
Hermes Investment Management
United Kingdom
$2.12M +$1.92M +45,613 New
CIC
92
Cornercap Investment Counsel
Georgia
$2.1M +$23.8K +565 +1%
BAMCO Inc
93
BAMCO Inc
New York
$2.09M +$1.89M +45,000 New
OAM
94
Oxford Asset Management
United Kingdom
$2.08M +$609K +14,463 +50%
PI
95
PineBridge Investments
New York
$1.96M +$440K +10,460 +33%
First Trust Advisors
96
First Trust Advisors
Illinois
$1.96M +$266K +6,323 +18%
PI
97
Putnam Investments
Massachusetts
$1.92M -$14.9K -353 -0.8%
FIM
98
Freedom Investment Management
Connecticut
$1.85M +$122K +2,894 +8%
State Board of Administration of Florida Retirement System
99
State Board of Administration of Florida Retirement System
Florida
$1.82M +$746K +17,726 +83%
Macquarie Group
100
Macquarie Group
Australia
$1.81M -$107K -2,546 -6%

EBS Hedge Fund Activity: Q4 2017 in Review

238 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2017, worth a combined $1.88B — up 25% from $1.5B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new EBS positions and 11 closed out — a net gain of 41 holders — while 104 added to existing stakes and 60 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $24.3M. The largest seller was Glenmede Trust, cutting an estimated $22.3M.

  • 238 institutional investors held Emergent Biosolutions (EBS) as of Q4 2017, up from 198 in Q3 2017.
  • Funds reported $1.88B of Emergent Biosolutions stock for Q4 2017, up 25% quarter-over-quarter.
  • 52 funds opened new Emergent Biosolutions positions in Q4 2017 and 11 closed out, a net change of +41 holders.
  • The largest Emergent Biosolutions buyer in Q4 2017 was Goldman Sachs, an estimated $24.3M added.
  • The largest Emergent Biosolutions seller in Q4 2017 was Glenmede Trust, an estimated $22.3M sold.

Based on aggregated 13F filings for Q4 2017.